Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)

Abstract A 66‐year‐old man with squamous cell carcinoma had been receiving chemoradiation therapy after stereotactic radiotherapy for brain metastases. Atezolizumab was initiated as second‐line therapy, after which the patient became progression‐ and recurrence‐free. Four days after his second dose...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Toshiyuki Sumi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	hemoptysis lung cancer tozinameran vaccine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b19949a1ae4845508d85bac3487a9988
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b19949a1ae4845508d85bac3487a9988
record_format	dspace
spelling	oai:doaj.org-article:b19949a1ae4845508d85bac3487a99882021-11-14T23:28:26ZLung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)1759-77141759-770610.1111/1759-7714.14179https://doaj.org/article/b19949a1ae4845508d85bac3487a99882021-11-01T00:00:00Zhttps://doi.org/10.1111/1759-7714.14179https://doaj.org/toc/1759-7706https://doaj.org/toc/1759-7714Abstract A 66‐year‐old man with squamous cell carcinoma had been receiving chemoradiation therapy after stereotactic radiotherapy for brain metastases. Atezolizumab was initiated as second‐line therapy, after which the patient became progression‐ and recurrence‐free. Four days after his second dose of tozinameran (BNT162b2, Pfizer‐BioNTech), the patient developed persistent hemoptysis. The patient had no thrombocytopenia or coagulation abnormalities. Bronchoscopy revealed active bleeding from the left lingual tracheal branch. The patient was intubated and admitted to the intensive care unit because of increased bleeding. Subsequently, left bronchial artery embolization was performed using a Serescue. Hemostasis was achieved after the procedure, and the patient was discharged 7 days after the onset of hemoptysis. Vaccination against coronavirus disease has been reported to be associated with thrombosis and cerebral hemorrhage, and the hemoptysis in this case was suspected to be induced by vaccination. In summary, the benefits of vaccination exceeded the risks of adverse events in a patient with cancer. However, in conditions such as after chemoradiation, especially in patients with radiation pneumonitis wherein the vasculature is vulnerable, patients should be carefully monitored for hemorrhagic events after vaccination.Toshiyuki SumiYuta NagahisaKeigo MatsuuraMotoki SekikawaYuichi YamadaHisashi NakataHirofumi ChibaWileyarticlehemoptysislung cancertozinameranvaccineNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENThoracic Cancer, Vol 12, Iss 22, Pp 3072-3075 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hemoptysis lung cancer tozinameran vaccine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hemoptysis lung cancer tozinameran vaccine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Toshiyuki Sumi Yuta Nagahisa Keigo Matsuura Motoki Sekikawa Yuichi Yamada Hisashi Nakata Hirofumi Chiba Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
description	Abstract A 66‐year‐old man with squamous cell carcinoma had been receiving chemoradiation therapy after stereotactic radiotherapy for brain metastases. Atezolizumab was initiated as second‐line therapy, after which the patient became progression‐ and recurrence‐free. Four days after his second dose of tozinameran (BNT162b2, Pfizer‐BioNTech), the patient developed persistent hemoptysis. The patient had no thrombocytopenia or coagulation abnormalities. Bronchoscopy revealed active bleeding from the left lingual tracheal branch. The patient was intubated and admitted to the intensive care unit because of increased bleeding. Subsequently, left bronchial artery embolization was performed using a Serescue. Hemostasis was achieved after the procedure, and the patient was discharged 7 days after the onset of hemoptysis. Vaccination against coronavirus disease has been reported to be associated with thrombosis and cerebral hemorrhage, and the hemoptysis in this case was suspected to be induced by vaccination. In summary, the benefits of vaccination exceeded the risks of adverse events in a patient with cancer. However, in conditions such as after chemoradiation, especially in patients with radiation pneumonitis wherein the vasculature is vulnerable, patients should be carefully monitored for hemorrhagic events after vaccination.
format	article
author	Toshiyuki Sumi Yuta Nagahisa Keigo Matsuura Motoki Sekikawa Yuichi Yamada Hisashi Nakata Hirofumi Chiba
author_facet	Toshiyuki Sumi Yuta Nagahisa Keigo Matsuura Motoki Sekikawa Yuichi Yamada Hisashi Nakata Hirofumi Chiba
author_sort	Toshiyuki Sumi
title	Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
title_short	Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
title_full	Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
title_fullStr	Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
title_full_unstemmed	Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
title_sort	lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (bnt162b2, pfizer‐biontech)
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/b19949a1ae4845508d85bac3487a9988
work_keys_str_mv	AT toshiyukisumi lungsquamouscellcarcinomawithhemoptysisaftervaccinationwithtozinameranbnt162b2pfizerbiontech AT yutanagahisa lungsquamouscellcarcinomawithhemoptysisaftervaccinationwithtozinameranbnt162b2pfizerbiontech AT keigomatsuura lungsquamouscellcarcinomawithhemoptysisaftervaccinationwithtozinameranbnt162b2pfizerbiontech AT motokisekikawa lungsquamouscellcarcinomawithhemoptysisaftervaccinationwithtozinameranbnt162b2pfizerbiontech AT yuichiyamada lungsquamouscellcarcinomawithhemoptysisaftervaccinationwithtozinameranbnt162b2pfizerbiontech AT hisashinakata lungsquamouscellcarcinomawithhemoptysisaftervaccinationwithtozinameranbnt162b2pfizerbiontech AT hirofumichiba lungsquamouscellcarcinomawithhemoptysisaftervaccinationwithtozinameranbnt162b2pfizerbiontech
_version_	1718429004567937024

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)

Ejemplares similares